Latest Insights - page 11 | BiopharmaTrend

AstraZeneca Acquires Modella AI to Integrate Foundation Models into Global Oncology R&D

AstraZeneca has acquired Boston-based Modella AI to scale the integration of multimodal foundation models and AI agents across its oncology research and development programs. The deal follows a collaboration between …

Continue ›››

Illumina Launches Billion-Cell CRISPR Dataset for AI-Driven Drug Discovery, Built with AstraZeneca, Merck, and Lilly

Illumina has unveiled the Billion Cell Atlas, a large-scale CRISPR perturbation dataset aimed at accelerating drug discovery by enabling AI training on real biological responses of more than 1 billion …

Continue ›››

VantAI Renames, Raises $80M to Scale AI Platform for Proximity-Based Drug Discovery

Proxima, formerly known as VantAI (Roivant spinout founded in 2019), has secured $80 million in seed funding to expand its AI-driven drug discovery platform for proximity-based therapeutics. The round was …

Continue ›››

Immunai Offers Free Single-Cell Multi-Omics To Three Academic Centers While Growing Its AI Atlas

Immunai has selected researchers from Mount Sinai, Weill Cornell Medicine, and Massachusetts General Hospital to join its academic collaboration initiative focused on advancing understanding of the human immune system. The …

Continue ›››

Thermo Fisher Teams With NVIDIA and TetraScience to Bring AI Into the Lab

Thermo Fisher Scientific has announced a strategic collaboration with NVIDIA to integrate AI infrastructure across Thermo Fisher’s scientific instruments and laboratory systems. The companies aim to automate routine workflows and …

Continue ›››

Anthropic Launches Claude for Healthcare at JPM26

Anthropic has announced the launch of Claude for Healthcare, a version of its large language model suite configured for clinical providers and patients. The release was timed with the start …

Continue ›››

NVIDIA and Lilly Launch $1B AI Co-Innovation Hub for Drug Discovery in South San Francisco

Eli Lilly and NVIDIA announced at the January 12, 2026 J.P. Morgan Healthcare Conference in San Francisco that they are creating a new AI co-innovation lab in South San Francisco, …

Continue ›››

Owkin Partners with NVIDIA, Rolls Out Multimodal Agent Platform Integrated with Claude

Owkin has entered its first collaboration with NVIDIA to advance the development of its biological large reasoning model, OwkinZero, using NVIDIA’s open AI infrastructure and reinforcement learning toolkit. Announced today …

Continue ›››

After IPO, AI Drug Developer Insilico Medicine Advances Gut-Restricted PHD Inhibitor Into Phase II IBD Trial

Insilico Medicine reported first patient first dose in a Phase IIa clinical trial of its gut-restricted PHD inhibitor ISM5411, now assigned the generic name garutadustat. The milestone moves the AI-designed …

Continue ›››

Manas AI and Schrödinger Partner on Deep Integration of Physics-Based Modeling into AI Drug Discovery Platform

LinkedIn founder Reid Hoffman and Siddhartha Mukherjee’s Manas AI has entered a multi-year strategic agreement with Schrödinger, securing privileged access to its physics-based molecular modeling platform along with direct engagement …

Continue ›››

MIT Team Behind Boltz Launches With $28M, Pfizer Collaboration, and Three Guarantees

Boltz has launched as a public benefit corporation and paired the company formation with three operational announcements: a $28 million seed financing, a multi-year collaboration with Pfizer, and a preview …

Continue ›››

CRISPR’s First One-Patient Success Is Becoming a Company: Aurora Launches With $16M to Scale Bespoke Gene Editing

Aurora Therapeutics has launched with $16 million in seed funding from Menlo Ventures to pursue bespoke CRISPR-based therapies for ultra-rare genetic diseases. The company is founded by CRISPR co-inventor Dr. …

Continue ›››